OTLK.NASDAQOutlook Therapeutics, INC

10-Q: Outlook Therapeutics Reports Q2 2025 Results, BLA Resubmission Under FDA Review

Sentiment:

Quarterly Report

📋All filings for Outlook Therapeutics, INC
🔒Login to Follow

Outlook Therapeutics resubmitted its BLA for ONS-5010/LYTENAVA and is awaiting an FDA decision by August 27, 2025, while preparing for a potential EU/UK launch in Q2 2025.

Capital raiseThe company is evaluating strategies to obtain funding, including licensing agreements, equity issuances, and debt financing.The company may issue additional debt or equity securities, including accessing capital through at-the-market offering agreements.The company issued an unsecured convertible promissory note for $33.1 million to Avondale Capital in March 2025.The company completed a warrant inducement transaction, generating $15.9 million in net proceeds.The company sold 1,926,742 shares of common stock under the ATM Offering, generating approximately $3.2 million in net proceeds.
Worse than expectedThe NORSE EIGHT trial did not meet the pre-specified non-inferiority endpoint at week 8 set forth in the SPA.There is substantial doubt about the company's ability to continue as a going concern.

Summary

  • Outlook Therapeutics, Inc. reported its financial results for the quarter ended March 31, 2025.
  • The company is focused on developing and commercializing ONS-5010/LYTENAVA for retinal indications.
  • In May 2024, the European Commission granted Marketing Authorization for ONS-5010/LYTENAVA in the EU, and in July 2024, the MHRA granted authorization in the UK.
  • The company resubmitted its Biologics License Application (BLA) to the FDA for ONS-5010/LYTENAVA in February 2025.
  • The FDA has set a PDUFA goal date of August 27, 2025, for a decision on the BLA.
  • The company's net loss for the six months ended March 31, 2025, was $28.98 million, compared to a net loss of $125.47 million for the same period in 2024.
  • Research and development expenses decreased to $14.07 million for the six months ended March 31, 2025, from $18.04 million in 2024.
  • General and administrative expenses increased to $19.93 million for the six months ended March 31, 2025, from $11.22 million in 2024, due to prelaunch expenses in Europe and increased compensation costs.
  • The company had cash and cash equivalents of $7.56 million as of March 31, 2025, and anticipates needing additional financing to fund operations.
  • There is substantial doubt about the company's ability to continue as a going concern.
  • The company is evaluating strategies to obtain funding, including licensing agreements, equity issuances, and debt financing.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While the company has achieved regulatory milestones in the EU and UK and resubmitted its BLA to the FDA, there are significant financial challenges, including recurring losses, a working capital deficit, and substantial doubt about its ability to continue as a going concern. The need for additional financing and the uncertainty surrounding the FDA approval process contribute to the negative outlook.

Positives

  • The company received Marketing Authorization for ONS-5010/LYTENAVA in the EU and UK.
  • The company resubmitted its BLA for ONS-5010/LYTENAVA to the FDA.
  • The net loss decreased significantly compared to the same period last year.
  • The company completed a warrant inducement transaction, generating $15.9 million in net proceeds.
  • The company sold 1,926,742 shares of common stock under the ATM Offering, generating approximately $3.2 million in net proceeds.

Negatives

  • The company has incurred recurring losses and negative cash flows from operations since its inception.
  • The company has an accumulated deficit of $572.26 million as of March 31, 2025.
  • The company has a working capital deficit as of March 31, 2025.
  • There is substantial doubt about the company's ability to continue as a going concern.
  • The company needs additional financing to fund its operations.

Risks

  • The company's future operations are highly dependent on obtaining additional financing.
  • The company's ability to successfully commercialize ONS-5010/LYTENAVA is uncertain.
  • The company faces risks associated with the development of competitive therapies.
  • The company's ability to obtain regulatory approval and market acceptance of its proposed future products is uncertain.
  • Global uncertainty due to tariffs and macroeconomic conditions may have a material adverse effect on the rollout of LYTENAVA.
  • The company is subject to a securities class action lawsuit and a shareholder derivative action.

Future Outlook

The company plans to focus on supporting the review of its BLA submission for ONS-5010/LYTENAVA with the FDA and preparing for the potential launch of ONS-5010/LYTENAVA, if approved, to support the generation of commercial revenues. The company anticipates it will incur net losses and negative cash flow from operations for the foreseeable future.

Industry Context

The document highlights Outlook Therapeutics' efforts to commercialize ONS-5010/LYTENAVA, an ophthalmic formulation of bevacizumab, for the treatment of wet AMD. The company aims to capture a significant share of the anti-VEGF retina market, estimated to be approximately $16 billion globally. The company believes ONS-5010/LYTENAVA has potential to mitigate risks associated with off-label use of unapproved bevacizumab.

Comparison to Industry Standards

  • The document mentions that off-label repackaged bevacizumab is a frequently used first-line anti-VEGF treatment in Europe (approximately 2.8 million injections annually) and the United States (approximately 2.7 million injections annually).
  • The company estimates the global market for anti-VEGF retina to be approximately $16 billion (Citeline (2023), Global Data (2023) and Market Scope (2022)).
  • The document references ranibizumab (LUCENTIS) as a comparator drug in the NORSE TWO clinical trial.
  • The document references a $3.6 billion anti-VEGF retina market in Europe.
  • The document references an $8.5 billion anti-VEGF retina market in the United States.

Legal Proceedings

  • A securities class action lawsuit was filed against the company and certain of its officers in the United States District Court for the District of New Jersey.
  • Certain of the company's officers and directors were named as defendants in a shareholder derivative action filed in the District Court of the District of Delaware.

Stakeholder Impact

  • Shareholders face potential dilution from future equity issuances.
  • Employees may be affected by potential workforce reductions.
  • Customers (patients) may benefit from the potential approval and commercialization of ONS-5010/LYTENAVA.
  • Suppliers and creditors face risks associated with the company's financial instability.

Next Steps

  • Support the review of the BLA submission for ONS-5010/LYTENAVA with the FDA.
  • Prepare for the potential launch of ONS-5010/LYTENAVA in the EU and UK in Q2 2025.
  • Obtain additional financing to fund operations.
  • Execute marketing arrangements or complete revenue-generating partnerships with other companies.

Key Dates

DateDescription
January 5, 2010Outlook Therapeutics, Inc. was incorporated in New Jersey.
December 22, 2017Date of the Note and Warrant Purchase Agreement related to convertible senior secured notes.
April 2018End of Phase 2 meeting with the FDA to review the study design for the clinical program to evaluate ONS-5010/LYTENAVA.
First quarter of calendar 2019The company filed its investigational new drug application, or IND, with the FDA.
May 22, 2020Execution of a stock purchase agreement with Syntone Ventures, LLC.
June 2020The company made the initial investment of $900,000 in Syntone JV.
August 2020The company reported achieving the anticipated safety and efficacy proof-of-concept results from NORSE ONE.
March 2021The company reported that the results from NORSE THREE showed a positive safety profile for ONS-5010/LYTENAVA.
March 2021The company entered into a three-year term corporate office lease for its former corporate headquarters in Iselin, New Jersey.
April 2021Formation of Syntone JV.
August 2021The topline results reported from NORSE TWO showed that ONS-5010/LYTENAVA met the primary and key secondary endpoints for efficacy.
November 2021The company began enrolling patients in its NORSE SEVEN clinical trial.
March 2022The company submitted a BLA with the FDA for ONS-5010/LYTENAVA for the treatment of wet AMD.
May 2022The company voluntarily withdrew its BLA to provide additional information requested by the FDA.
May 16, 2023The company entered into an At-the-Market Sales Agreement with BTIG, LLC.
August 29, 2023The company received a Complete Response Letter (CRL) from the FDA.
November 3, 2023A securities class action lawsuit was filed against the company and certain of its officers.
December 2023The company submitted a Special Protocol Assessment (SPA) to the FDA for the NORSE EIGHT study.
January 2024The company received confirmation that the FDA had reviewed and agreed upon the NORSE EIGHT trial protocol pursuant to the SPA.
January 22, 2024The company entered into an amendment to the December 2022 Note with the Lender.
March 14, 2024Effective date of the one-for-twenty reverse stock split of its common stock.
March 18, 2024The company issued an aggregate of 8,571,423 shares of common stock and warrants to purchase an aggregate of 12,857,133 shares of common stock in a private placement.
April 1, 2024The amendment to the December 2022 Note became effective.
April 15, 2024The company issued 714,286 shares of common stock and accompanying warrants to purchase 1,071,429 shares of common stock in a private placement with Syntone.
April 30, 2024End date of the three-year term corporate office lease for its former corporate headquarters in Iselin, New Jersey.
May 2024The European Commission granted the Marketing Authorization for ONS-5010/LYTENAVA for the treatment of wet AMD in the EU.
May 1, 2024Commencement date of the five-year term corporate office lease for its new corporate headquarters in Iselin, New Jersey.
July 2024The MHRA granted marketing authorization for ONS-5010/LYTENAVA for the treatment of wet AMD in the UK.
August 2024The company's stockholders approved the amendment and restatement of the 2015 Plan, at which time, the name of the 2015 Plan was updated to the Outlook Therapeutics, Inc. 2024 Equity Incentive Plan.
September 2024NORSE EIGHT clinical trial completed enrollment.
November 2024The company reported that ONS-5010/LYTENAVA did not meet the pre-specified non-inferiority endpoint at week 8 set forth in the SPA.
January 16, 2025The company entered into warrant inducement agreements with GMS Ventures and certain other holders of warrants issued in the Private Placement to exercise warrants for 7,074,637 shares of common stock.
January 2025The company reported the complete data and safety results from NORSE EIGHT.
January 31, 2025Date of the Securities Purchase Agreement (SPA) related to the March 2025 Note.
February 6, 2025The court entered an order granting the motion to dismiss and dismissing the complaint without prejudice and with leave to amend.
February 2025The company resubmitted the BLA application for ONS-5010/LYTENAVA.
March 11, 2025Certain terms of the March 2025 Note were approved at the company's annual meeting of stockholders.
March 13, 2025The company issued the March 2025 Note for $33,100,000 to Avondale Capital, LLC.
March 14, 2025The plaintiffs filed their second amended class action complaint.
March 28, 2025The company filed a registration statement registering the resale of common stock issuable upon conversion of the March 2025 Note.
March 31, 2025End of the quarterly period.
April 2025The company received notification from the FDA that the Prescription Drug User Fee Act (PDUFA) goal date for a decision on the BLA is August 27, 2025.
April 10, 2025Retention Bonus Letter, dated April 10, 2025, by and between the Company and Lawrence A. Kenyon.
April 23, 2025The defendants filed a motion to dismiss the plaintiffs second amended class action complaint in its entirety.
May 15, 2025Date of the filing of the Quarterly Report on Form 10-Q.
August 27, 2025PDUFA goal date for a decision on the BLA.
July 1, 2026The March 2025 Note is scheduled to mature.

Keywords

ONS-5010/LYTENAVA, wet AMD, BLA, FDA, Marketing Authorization, EU, UK, Avondale Capital, Streeterville Capital, Syntone, Warrant Inducement Transaction, ATM Offering, Biopharmaceutical, Retinal Indications, Bevacizumab

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.